Drug Profile


Alternative Names: Ibrance; PD-0332991; PD-332991; PD-991; PF-332991

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Onyx Pharmaceuticals; Pfizer
  • Developer Assistance Publique Hopitaux de Paris; Canadian Cancer Trials Group; Dana-Farber Cancer Institute; Georgetown University; German Breast Group; GlaxoSmithKline; iOMEDICO AG; Karolinska Institute; Merck & Co; National Cancer Institute (USA); Netherlands Cancer Institute; Northwestern University; Pfizer; UNC Lineberger Comprehensive Cancer Center; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclopentanes; Ketones; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Brain metastases; Colorectal cancer; Head and neck cancer; Prostate cancer; Urogenital cancer
  • Phase I/II Cancer; Malignant melanoma
  • Phase I Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Mantle-cell lymphoma; Pancreatic cancer; Solid tumours
  • No development reported Glioblastoma; Multiple myeloma

Most Recent Events

  • 09 Aug 2017 Pfizer and Dana-Farber Cancer Institute initiates enrolment in a phase-II trial for Breast cancer (Combination therapy, Recurrent, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT03147287)
  • 25 Jul 2017 Phase-I clinical trials in Acute myeloid leukaemia and Acute lymphoblastic leukaemia (Second-line therapy or greater, Monotherapy, Combination therapy) in USA (PO) (NCT03132454)
  • 21 Jul 2017 Pfizer initiates a phase I drug-interaction trial in Healthy volunteers in USA (NCT03220191)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top